Agios Pharma | BiotechTV

top of page

Pyruvate kinase activation as a sickle cell disease strategy with Agios' CEO at #ASH23

Brian Goff highlights data from the phase 2 portion of the RISE UP pivotal study of Mitapivat for SCD that was presented at #ASH23 today.

Company News

Dec 11, 2023

Agios on today’s phase 2 data for the pyruvate kinase activator mitapivat in sickle cell disease

Agios CEO Brian Goff on today's p2 SCD data and how he thinks maitapivat fits into the competitive landscape.

Company News

Jun 26, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page

Pyruvate kinase activation as a sickle cell disease strategy with Agios' CEO at #ASH23

Agios on today’s phase 2 data for the pyruvate kinase activator mitapivat in sickle cell disease

Follow BiotechTV

Sponsors

Sponsor Spotlight